A Long-term Extension Study of PCI-32765 (Ibrutinib)

Key facts

Sponsor

Janssen Research & Development, LLC

Principal Investigator

Janssen Research & Development, LLC Clinical Trial

Janssen Research & Development, LLC

Intervention

Ibrutinib(drug)

Enrollment

700 enrolled

Eligibility

18 years · All sexes

Timeline

2013 – 2027

Study locations (30)

• City of Hope Cancer Center, Duarte, California, United States
• University of California San Diego Medical Center, La Jolla, California, United States
• University of California Los Angeles, Los Angeles, California, United States
• St. Joseph Hospital Center for Cancer Prevention and Treatment, Orange, California, United States
• Stanford University Medical Center, Stanford, California, United States
• Stanford University, Stanford, California, United States
• Norwalk Medical Group, Norwalk, Connecticut, United States
• Northwest Georgia Oncology Centers PC, Marietta, Georgia, United States
• Northwestern University Hospital, Chicago, Illinois, United States
• Indiana University, Goshen, Indiana, United States
• Kansas University Medical Center, Westwood, Kansas, United States
• Louisville Oncology Suburban - Norton Cancer Institute, Louisville, Kentucky, United States
• Dana Farber Cancer Center, Boston, Massachusetts, United States
• University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
• Battle Creek Health Systm, Battle Creek, Michigan, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

Pharmacyclics LLC.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07194980
  Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  Fred Hutchinson Cancer Center
• RECRUITINGEARLY PHASE1NCT07428707
  Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
  National Heart, Lung, and Blood Institute (NHLBI)
• RECRUITINGPHASE4NCT07218341
  A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  Eli Lilly and Company
• RECRUITINGPHASE1NCT06859008
  Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  City of Hope Medical Center
• RECRUITINGPHASE2NCT07271667
  A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
  Curis, Inc.
• RECRUITINGPHASE2NCT07014917
  Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
  Zulfa Omer
• RECRUITINGPHASE2NCT06958705
  Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
  The First Affiliated Hospital with Nanjing Medical University
• RECRUITINGPHASE1, PHASE2NCT07052695
  Mosunetuzumab for CLL MRD Clearance
  Inhye Ahn

See all trials for B-cell chronic lymphocytic leukemia →